Estrogen receptor ligands and methods of use thereof 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(KR101458539) 에스트로겐 수용체 리간드 및 그 이용 방법
公开号/公开日
KR20110131227 A 2011-12-06 [KR20110131227]KR101458539 B1 2014-11-10 [KR101458539] / 2011-12-062014-11-10
申请号/申请日
2011KR-7022324 / 2010-02-23
发明人
DALTON JAMES T;STEINER MITCHELL S;
申请人
GTX;
主分类号
IPC分类号
A01N-043/40A61K-031/445C07C-233/64
摘要
(KR101458539) The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting advanced prostate cancer and palliative treatment of advanced prostate cancer.  (From WO2010096801 A1)
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2009US-61154707 2009-02-23 2009US-61168983 2009-04-14 2009US-61261669 2009-11-16 2010WO-US25032 2010-02-23
主权利要求
(KR101458539)  Claims machine translated from Korean 1. The chemical compound or that isomer of style I of therapeutic effective quantity, pharmacy the permission possible salt, the pharmacy product and the polymorph body, to include the luggage or different meaning union, treats a progressive prostate cancer from the male objective body the pharmacy composition for: From minute description style, Y is C (O) or CH [2];   R [1] and R [2] to be the hydrogen and the halogen, independently, the de rock thread, alkoxy and poem Roh, Nitro, CF [3], N (r) [2], the sulphonamide and SO [2] R and the alkyl, do with the alkyl, will be biting, and O-Alk-NR [5] R [6] or to be a O-Alk-hetero cycle, minute description hetero cycle being 3-7 won replacement or a beach annular hetero cycle link;   R [3] and [] R [4] will be the hydrogen, the halogen and the hydroxy alkyl, independently, the de rock thread, alkoxy and poem Roh, Nitro, CF [3], NHCOR and N (r) [2], the sulphonamide and SO [2] R and the alkyl, will do, with the alkyl, will be biting or was protected to be, is a de rock practical technique;   R does the alkyl and the hydrogen, will do with the alkyl and D will do with the alkyl and tree with the alkyl and CH [2] F, [] CHF [2], [] CF [3], CF [2] CF [3], will be biting, the phenyl, the halogen and the egg do, Neel and CN, NO [2], or being OH;   R [5] and R [6] independently the hydrogen, the phenyl, carbon atom 1 to alkyl and 3-7 won claw alkyl of 6, 3-7 won hetero cycles, 5-7 won is biting.  R [5] and R [6] with the nitrogen atom forms 3-7 won links;   j and k independently are 1 to 4. And As for Alk the basin style alkyl of the linear alkyls and 1-7 carbon of 1-7 carbon, or being click alkyl of 3-8 carbon. 2. Elimination 3. There is in a 1st claim, The chemical compound of minute description style I from after is selected the pharmacy composition the fact that with feature: And 4. There is in a 1st claim, The treatment of minute description progressive prostate cancer being attained, by lowering the total serum testosterone or the free serum testosterone the fact that the minute description total serum testosterone or the free serum testosterone lowering by the reduction on serum luteinizing hormone(LH) level is happens, the pharmacy composition. 5. There is in a 1st claim, The treatment of minute description progressive prostate cancer being attained, by lowering the total serum testosterone or the free serum testosterone the fact that the minute description total serum testosterone or the free serum testosterone lowering reduction on serum luteinizing hormone(LH) level and unrelated is be, the pharmacy composition. 6. There is in a fifth claim, The reduction of the minute description total serum testosterone or the free serum testosterone soaks sex hormone combination writing base and (SHBG) within increase and the testis is a Lae D, a thing caused by the testosterone production by the cell or secretion suppression or adrenal steroid production reduction is, the pharmacy composition. 7. There is in a 6th claim, The minute description total serum testosterone includes the free testosterone and the combination testosterone, and the serum luteinizing hormone(LH) level reduction and reduction on the unrelated minute description free testosterone level be caused by SHBG increase are the thing, the pharmacy composition. 8. Elimination 9. Is in the fourth claim or the fifth claim, The minute description total serum testosterone is reduced 100 ng/dL, 50 ng/dL or below 25 ng/dL the pharmacy composition the fact that with feature. 10. Is in the fourth claim or the fifth claim, The medication of the minute description pharmacy composition androgen interception medical therapy (ADT) with does not cause the side effect which relates, the total serum testosterone or the free serum testosterone at the time of reduction as for height the pharmacy composition thing with feature. 11. Is in the fourth claim or the fifth claim, The medication of the minute description pharmacy composition hot flash and the feminine style breast, does not cause the bone density reduction or a fracture increase, the total serum testosterone or the free serum testosterone at the time of reduction as for height the pharmacy composition thing with feature. 12. There is in a 11th claim, As for the minute description total serum testosterone or free serum testosterone reduction by a serum luteinizing hormone(LH) level reduction happens the pharmacy composition the fact that with feature. 13. There is in a 11th claim, As for the minute description total serum testosterone or free serum testosterone reduction serum luteinizing hormone(LH) reduction and unrelated be the pharmacy composition the fact that with feature. 14. Elimination 15. There is in a 1st claim, The minute description pharmacy composition in addition suppresses a progressive prostate cancer the occurrence at the time of reduction the height thing or the seriousness at the time of reduction the height thing or, or as for under hindering the pharmacy composition thing with feature. 16. There is in a 1st claim, The minute description pharmacy composition in addition relaxation treatment of progressive prostate cancer as for under providing the pharmacy composition thing with feature. 17. Elimination 18. Elimination 19. Elimination 20. Elimination 21. Elimination 22. Elimination 23. Elimination 24. Elimination 25. Elimination 26. Elimination 27. Elimination 28. Elimination 29. Elimination 30. Elimination 31. Elimination 32. Elimination 33. Elimination 34. Elimination 35. Elimination 36. Elimination 37. Elimination 38. Elimination 39. Elimination 40. Elimination 41. Elimination 42. Elimination 43. Elimination 44. Elimination 45. Elimination 46. Elimination 47. Elimination 48. Elimination 49. Elimination 50. Elimination 51. Elimination 52. Elimination
法律状态
(KR101458539) LEGAL DETAILS FOR KR20110131227  Actual or expected expiration date=2030-02-23    Legal state=ALIVE    Status=GRANTED     Event publication date=2010-02-23  Event code=KR/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=KR KR20117022324  Application date=2010-02-23  Standardized application number=2011KR-7022324     Event publication date=2011-10-25  Event code=KR/A201  Event type=Examination events  Request for examination    Event publication date=2011-12-06  Event code=KR/A  Event type=Examination events  Published application  Publication country=KR  Publication number=KR20110131227  Publication stage Code=A  Publication date=2011-12-06  Standardized publication number=KR20110131227     Event publication date=2013-05-31  Event code=KR/E902  Event indicator=Neg  Event type=Examination events  Notification of reason for refusal    Event publication date=2013-07-30  Event code=KR/A107  Event type=Examination events  Divisional application of patent    Event publication date=2013-11-29  Event code=KR/E902  Event indicator=Neg  Event type=Examination events  Notification of reason for refusal    Event publication date=2014-05-20  Event code=KR/E90F  Event indicator=Neg  Event type=Examination events  Notification of reason for final refusal    Event publication date=2014-09-26  Event code=KR/E701  Event indicator=Pos  Event type=Event indicating In Force  Decision to grant or registration    Event publication date=2014-11-10  Event code=KR/B1  Event indicator=Pos  Event type=Event indicating In Force  Patent specification  Publication country=KR  Publication number=KR101458539  Publication stage Code=B1  Publication date=2014-11-10  Standardized publication number=KR101458539
专利类型码
AB1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部